Piper Sandler Boosts Century Therapeutics (NASDAQ:IPSC) Price Target to $12.00

Century Therapeutics (NASDAQ:IPSCFree Report) had its target price hoisted by Piper Sandler from $9.00 to $12.00 in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

IPSC has been the topic of several other research reports. HC Wainwright restated a buy rating and issued a $11.00 price target on shares of Century Therapeutics in a research note on Tuesday, June 4th. Canaccord Genuity Group raised their price target on Century Therapeutics from $22.00 to $24.00 and gave the company a buy rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $13.80.

Check Out Our Latest Stock Analysis on Century Therapeutics

Century Therapeutics Stock Down 5.7 %

NASDAQ IPSC opened at $2.97 on Monday. The firm has a market capitalization of $246.06 million, a PE ratio of -1.34 and a beta of 1.44. The stock’s 50 day moving average is $3.14 and its 200 day moving average is $3.58. Century Therapeutics has a twelve month low of $1.28 and a twelve month high of $5.51.

Century Therapeutics (NASDAQ:IPSCGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. Century Therapeutics had a negative net margin of 9,742.41% and a negative return on equity of 59.74%. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.30 million. On average, research analysts anticipate that Century Therapeutics will post -1.94 earnings per share for the current year.

Hedge Funds Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP lifted its stake in Century Therapeutics by 23.4% during the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after acquiring an additional 256,500 shares during the period. Vanguard Group Inc. lifted its position in Century Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock valued at $4,760,000 after purchasing an additional 14,000 shares during the period. Federated Hermes Inc. boosted its holdings in Century Therapeutics by 0.4% in the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in Century Therapeutics by 191.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock worth $1,229,000 after purchasing an additional 192,915 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Century Therapeutics during the 1st quarter valued at $47,000. 50.20% of the stock is owned by institutional investors.

Century Therapeutics Company Profile

(Get Free Report)

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.

See Also

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.